Abstract
Few studies have measured preference-based utility weights as evaluation of health-related quality of life under specific first-line treatments for advanced renal cell carcinoma (aRCC). This study assessed health state utilities and adverse event (AE)-related disutility among previously untreated patients with aRCC randomized to pembrolizumab/axitinib or sunitinib in a multinational phase III trial (KEYNOTE-426/NCT02853331).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
